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RhoJ/TCL Regulates Endothelial Motility and Tube
Formation and Modulates Actomyosin Contractility and
Focal Adhesion Numbers
Sukhbir Kaur, Katarzyna Leszczynska, Sabu Abraham, Margherita Scarcia, Sabina Hiltbrunner,
Christopher J. Marshall, Georgia Mavria, Roy Bicknell, Victoria L. Heath
Objective—RhoJ/TCL was identified by our group as an endothelial-expressed Rho GTPase. The aim of this study was to
determine its tissue distribution, subcellular localization, and function in endothelial migration and tube formation.
Methods and Results—Using in situ hybridization, RhoJ was localized to endothelial cells in a set of normal and cancerous
tissues and in the vasculature of mouse embryos; endogenous RhoJ was localized to focal adhesions by immunofluo-
rescence. The proangiogenic factor vascular endothelial growth factor activated RhoJ in endothelial cells. Using either
small interfering (si)RNA-mediated knockdown of RhoJ expression or overexpression of constitutively active RhoJ
(daRhoJ), RhoJ was found to positively regulate endothelial motility and tubule formation. Downregulating RhoJ
expression increased focal adhesions and stress fibers in migrating cells, whereas daRhoJ overexpression resulted in the
converse. RhoJ downregulation resulted in increased contraction of a collagen gel and increased phospho–myosin light
chain, indicative of increased actomyosin contractility. Pharmacological inhibition of Rho-kinase (which phosphorylates
myosin light chain) or nonmuscle myosin II reversed the defective tube formation and migration of RhoJ knockdown cells.
Conclusion—RhoJ is endothelial-expressed in vivo, activated by vascular endothelial growth factor, localizes to focal
adhesions, regulates endothelial cell migration and tube formation, and modulates actomyosin contractility and focal
adhesion numbers. (Arterioscler Thromb Vasc Biol. 2011;31:657-664.)
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Endothelial cells line all blood vessels and play a criticalrole in the formation of new vessels, or angiogenesis.
Angiogenesis is involved in physiological processes, such as
the female menstrual cycle, but also plays a key role in
pathologies, such as diabetic retinopathy and the growth and
metastasis of solid tumors.1 During angiogenesis, endothelial
cells perform a variety of functions, including degradation of
the extracellular matrix, migration, proliferation, lumen for-
mation, and vessel stabilization,2 and roles for the Rho
GTPases RhoA, Cdc42, and Rac1 have been identified in
many of these processes.3
Rho GTPases are molecular switches that cycle between
active GTP-bound and inactive GDP-bound forms. They
were initially identified as regulators of the actin cytoskeleton
but have subsequently been shown to be involved in many
cellular processes, such as vesicle trafficking, cytokinesis,
and gene expression.4 Actin stress fibers are contractile
components of the cytoskeleton that comprise bundles of
actin and myosin, known as actomyosin. The small Rho
GTPases, RhoA, -B, and -C, when activated, promote stress
fiber formation via their activation of Rho-kinase (ROCKI/II,
ROK/); ROCK phosphorylates a number of targets, result-
ing in increased myosin light chain (MLC) phosphorylation
and increased actomyosin contractility.5 Recently, it was
demonstrated that established tubes have greater levels of
phospho-MLC and that this is reduced on induction of
sprouting.6 Indeed, inhibition of ROCK or MLC phosphory-
lation was accompanied by an induction of Rac1-dependent
sprouting, suggesting that sprouting angiogenesis is both
accompanied by and requires a downregulation of actomyo-
sin contractility.7 Focal adhesions are large, dynamic protein
complexes that mediate connections between the extracellular
matrix and the intracellular cytoskeleton. They play a critical
role in mechanotransduction, and their coordinated assembly
and turnover are required for cell motility.8
Using a combination of bioinformatic and expression
analyses using reverse transcription and quantitative poly-
merase chain reaction, our laboratory previously identified
the small Rho GTPase RhoJ/TCL (TC10 like) as being highly
and specifically expressed by endothelial cells.9 RhoJ was
initially identified by 2 groups as being a novel Rho GTPase
related to TC10 (RhoQ),10,11 belonging to the Cdc42 subfam-
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ily of Rho GTPases. Cdc42 has a critical role in filopodia
formation,4 whereas TC10 mediates insulin-regulated meta-
bolic events12; in contrast, overexpressing constitutively ac-
tive or inactive forms of RhoJ modulated filamentous (f)-
actin formation.11,13,14 A role for RhoJ in the in vitro
differentiation of 3T3 L1 adipocytes has been demonstrated,15
and, like its close homolog TC10, increased levels of RhoJ-
GTP were stimulated by insulin treatment.10 Subsequent work
has shown that epitope-tagged, overexpressed RhoJ localized
to early and recycling endosomes, and a role for RhoJ in
regulating early endocytosis was identified.16
The aim of this study was to further explore the tissue
distribution, investigate the activation, and determine the role of
RhoJ in endothelial cells. We have identified a vascular expres-
sion pattern of RhoJ in both human tissue and mouse embryos
and demonstrated that endogenous RhoJ localizes to focal
adhesions. We have identified a critical role for this Rho GTPase
in mediating endothelial cell motility and tube formation. We
also demonstrate that RhoJ plays a role in modulating actomy-
osin contractility and focal adhesion numbers.
Methods
An expanded Methods section is available in the online Data
Supplement at http://atvb.ahajournals.org.
Primary and immortalized cell lines used were human umbilical
vein endothelial cells (HUVECs) (passage 1 to 6), human pericytes
from placenta (hPC-PL), human aortic smooth muscle cells,
HMEC-1 (human microvascular cell line-1), and HEK293T. For
small interfering (si)RNA knockdown, HUVECs were transfected
with 10 to 25 nmol/L negative control duplex (siControl), RhoJ
siRNA duplex 1 (5-CCACTGTGTTTGACCACTA-3), or RhoJ
siRNA duplex 2 (5-AGAAACCTCTCACTTACGA-3). Transfec-
tions were performed using either RNAiMAX Lipofectamine (In-
vitrogen) at a final concentration of 0.3% (vol/vol) or GeneFECTOR
(Venn Nova Inc). RNAiMAX was used for all experiments except
for the organotypic tube-forming assays and the phospho/total MLC
Western blotting. The inhibitors used were Y27632 (10 mol/L,
ROCK inhibitor) or blebbistatin (5 mol/L, nonmuscle myosin II
inhibitor). For lentiviral production the plasmids psPAX2 and
pMD2G were used with either pWPXL-GFP-daRhoJ(Q79L) or
pWPI (green fluorescent protein [GFP]). GFP-positive HUVECs
were sorted before performing assays. Changes in protein expression
were assessed by Western blotting.
Scratch wounding of monolayers was achieved using a plastic
pipette tip. 2D tube formation was assessed by plating cells on
natural Matrigel. In the organotypic tube-forming assay, HUVECs
were cocultured with confluent human dermal fibroblasts, and tubule
formation was quantified using the AngioSys software.6,7 Contrac-
tility was assessed using cell-mediated contraction of a type I
collagen gel.17 MLC2 phosphorylation was assessed by Western
blotting for phospho-MLC2 and total MLC2.7
In situ hybridization was performed on human tissue sections,
which were costained with digoxigenin-labeled riboprobes/anti-
digoxigenin–rhodamine combined with Ulex europaeus agglutinin
I–fluorescein. The whole-mount in situ hybridization protocol was
adapted from Piette et al18 and performed on embryonic day 9.5 mice
using digoxigenin-labeled probes to mouse RhoJ or von Willebrand
factor. Immunofluorescence was performed using anti-vinculin,
anti–pFAK-Y397, purified rabbit anti-RhoJ antisera, or phalloidin-
TRITC and imaged using confocal microscopy. Focal adhesions
were manually counted. Levels of actin fluorescence were measured
using the LSM 510 confocal software.
Details of experimental repetition are noted in the full and
supplemental figure legends in the online Data Supplement; all
assays were performed with at least 3 different HUVEC isolates.
Data are plotted with error bars representing SEM or are displayed as
box and whisker plots: these indicate the maximum, minimum, 25th
and 75th percentile, and median values. To test statistical differences
in defined pairs of groups, the Mann–Whitney test was performed
except for the scratch-wound and gel-contraction assays, where the
Student t test was used. Statistical significance is denoted as follows:
***P0.001, **P0.001 to 0.01, and *P0.01 to 0.05.
Results
RhoJ Is Expressed in Endothelial Cells
RhoJ expression was localized by in situ hybridization both
on human tissue sections and in the developing mouse
embryo. U europaeus agglutinin I was used as a marker of
endothelium, because it recognizes an endothelial specific
glycosylation,19 and this colocalized with RhoJ in endothelial
cells lining vessels in a number of adult human tissues (heart,
adrenal gland, lymph node, muscle, pancreas, placenta, liver,
lung, bladder cancer, bone cancer, and ovarian cancer).
However, expression was not found in the vessels of testis,
brain, kidney, stomach, colon, or rectal cancer (Figure 1A and
supplemental Figure I in the online Data Supplement). The
RhoJ probe also stained some nonendothelial cells, including
muscle, liver, and some cancer cells, suggesting that RhoJ
expression is not restricted to the endothelium. Because this
vessel-like expression pattern may be attributable to expression
of RhoJ by nonendothelial vessel cell types, its expression was
tested in human placental-derived pericytes and aortic smooth
muscles cells. Low levels of RhoJ message and protein were
found in isolates of both cell types at a level much lower than
that seen in endothelial cells (supplemental Figure II).
Whole-mount in situ hybridization was performed at embry-
onic day 9.5, the stage at which the vasculature is developing
and angiogenesis is occurring in the developing mouse.20 RhoJ,
like the endothelial expressed gene von Willebrand factor,21 is
expressed in the main trunk vessels and intersomitic vessels
(Figure 1B). These data are consistent with an endothelial
expression pattern of RhoJ in developing vessels.
To determine the intracellular localization of endogenous
RhoJ, purified rabbit polyclonal antiserum was developed and
validated using RhoJ knockdown in HUVECs or RhoJ
overexpression in a nonendothelial cell type (data not shown).
Using this reagent, RhoJ was localized in punctuate regions
of the cell, and costaining with anti-vinculin antibodies or
anti-phospho(397) FAK antibodies indicated that these struc-
tures were focal adhesions (Figure 1C). Because RhoJ is
closely related in structure and amino acid sequence to other
members of the Rho GTPase family, we established that
neither this RhoJ polyclonal antisera nor the RhoJ monoclo-
nal antibodies used in this study for Western blotting recog-
nized Cdc42, Rac1, or RhoA (supplemental Figure III).
RhoJ Plays a Role in Endothelial Cell Motility,
Growth, and Tube Formation
To determine whether RhoJ plays any role in endothelial cell
biology and angiogenesis, a series of assays were performed
using HUVECs with either siRNA-mediated knockdown of
RhoJ or overexpression of dominant-active RhoJ. Knock-
down of RhoJ protein was performed using 2 RhoJ-specific
duplexes (RhoJ D1 and RhoJ D2); as a control, cells were
either mock-transfected or transfected with a negative control
duplex (siControl). Angiogenesis requires both endothelial
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cell motility and proliferation. Chemokinetic motility was
assessed using a basic scratch-wound assay. A scratch was
made in a monolayer of HUVECs 2 days after transfection.
Unlike the control cells (mock and siControl), cells with
reduced RhoJ expression (RhoJ D1 and D2) did not migrate
to close the scratch; at 24 hours, there was still a region of
scratch evident (Figure 2A). The mean area of scratch
remaining at different time points was quantified from 3
independent experiments (Figure 2C), and statistically signif-
icant differences observed at 24 hours by comparing either of
the RhoJ siRNA duplex–treated groups with the siScramble
control. Mitomycin C was added to this assay to prevent cell
division, strongly suggesting that it is impaired cell motility
in the RhoJ knockdown cells, rather than a proliferative
defect, that prevented closure. The RhoJ knockdown effi-
ciently knocked down RhoJ protein levels (Figure 2E) but did
not alter the levels of Cdc42, Rac1, or RhoA in endothelial
cells (supplemental Figure IV). The absence of any interferon
response at duplex concentrations used for any of the various
assays was confirmed by monitoring expression of the inter-
feron inducible genes 2,5-oligoadenylate synthetase 122 and
IFN-stimulated gene of 20 kDa23 (data not shown).
The effect of expressing a GFP-tagged dominant active
Q79L mutant of RhoJ,11 permanently in the GTP-bound
active form, was also assessed. HUVECs were transduced
with lentivirus to express either GFP or GFP-daRhoJ; GFP-
expressing cells were then purified by cell sorting; expression
of the GFP or GFP-daRhoJ was confirmed by Western blotting
(Figure 2F and supplemental Figure VA). GFP-daRhoJ primar-
ily localized to the plasma membrane, where it was more
concentrated in focal adhesions, there was also some localization
to intracellular vesicles (supplemental Figure VB). By contrast
to the siRNA knockdown, the overexpression of GFP-daRhoJ
slightly but reproducibly accelerated wound closure in at least 3
Figure 1. RhoJ expression patterns. A, In situ hybridization of RhoJ in combination with U europaeus agglutinin I (endothelial cells) in human
tissue sections. B, In situ hybridization of RhoJ and von Willebrand factor (vWF) (endothelial marker) in mouse embryos. C, Immunofluores-
cence of RhoJ with anti-vinculin or anti-phospho (Y397) FAK. Detailed figure legends are included in the online Data Supplement.
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experiments (Figure 2B and 2D). However, variations in the
speed of wound closure between different HUVEC isolates
meant that significant differences are not revealed by performing
statistical tests on the combined data at different time points.
These data strongly suggest a role for RhoJ in mediating
endothelial cell movement.
The effect of RhoJ knockdown on endothelial cell prolif-
eration and chemotaxis was also assessed; there was slightly
reduced cell growth in RhoJ D1– or RhoJ D2–transfected
endothelial cells compared with mock- or siControl-
transfected cells (supplemental Figure VIA). This diminished
proliferation was not associated with any changes in the cell
cycle distribution, but small increases in the level of apoptosis
were observed (supplemental Figure VIB). Knockdown of
RhoJ also inhibited chemotaxis through the porous filters in
response to chemoattractant, again suggesting a role for RhoJ
in endothelial cell motility (supplemental Figure VIC).
Finally, endothelial tube formation was assessed both using
a Matrigel tube-forming assay and an organotypic angiogen-
esis assay. HUVECs transfected with RhoJ-specific siRNA
duplexes produced a more poorly connected network of cells
when plated on Matrigel, a solubilized basement membrane
extract, compared with the control-transfected cells. These
networks were less stable, with more cell retraction observed
at 24 hours (supplemental Figure VII).
In the organotypic assay, HUVECs are cocultured with
human dermal fibroblasts. The interaction of these cell types
results in the formation of endothelial derived tubules with
lumens that are embedded in naturally produced extracellular
matrix.24 This process is entirely dependent on the 2 major
angiogenic factors: basic fibroblast growth factor, present in
the culture media; and vascular endothelial growth factor
(VEGF), produced by the fibroblasts; and the resulting
tubules are highly reminiscent of capillaries formed during
angiogenesis in vivo.25,26 HUVECs were either mock-
transfected or transfected with control or RhoJ-specific
siRNA duplexes and seeded on to a confluent monolayer of
human dermal fibroblasts, and tubules were allowed to
develop for 5 days. Knockdown of RhoJ resulted in highly
impaired tube formation in this assay, with there being
significantly fewer, shorter, and lesser-branched tubes (Fig-
ure 3A and 3B). Knockdown of RhoJ was assessed by
Western blotting at later time points, transfection with RhoJ
D1 and D2 at 20 nmol/L gave a knockdown of approximately
60% and 40%, respectively, after 4 days (supplemental
Figure VIII).
In contrast, HUVECs overexpressing GFP-daRhoJ produced
a greater number of highly branched tubules with a shorter mean
length (Figure 3C and 3D). These data indicate a role for RhoJ
in tubule formation in these assays. siRNA-mediated knock-
down of RhoJ in the human microvascular cell line HMEC-1
(human microvascular cell line-1) also resulted in impaired
scratch-wound closure (supplemental Figure IX) and tube for-
mation on Matrigel (supplemental Figure X).
Because tube formation is VEGF-dependent in the coculture
assay,26 and VEGF is one of the most potent proangiogenic
factors, assays were performed to assess whether RhoJ is
activated by VEGF. HUVECs were treated with VEGF, and
levels of both active RhoJ and Cdc42 were determined by pull
down of the active GTP-bound forms of these proteins with a
glutathione S-transferase fusion of the PAK1 CRIB domain and
Western blotting. Densitometry was performed and levels of
active Cdc42 and RhoJ in pull-downs versus cellular lysates
were determined. Activation of Cdc42 peaked at 15 minutes, and
its activity declined thereafter, a result consistent with previous
reports.27 RhoJ, like Cdc42, was activated by VEGF, but its level
of activation was more modest, with a slower and more
sustained induction (supplemental Figure XI).
RhoJ Modulates Actomyosin Contractility, Actin
Stress Fibers, and Focal Adhesions
The data thus far have implicated a critical role for RhoJ in
regulating endothelial cell motility, and because Rho GTPases
Figure 2. RhoJ regulates endothelial cell
motility. HUVECs were transfected with
siControl or RhoJ siRNA duplexes or
were mock-transfected (concentration:
10 nmol/L) (A, C, and E) or lentivirally
transduced to express GFP or GFP-
daRhoJ (B, D, and F). Scratch-wound
assays were performed (A and B), clo-
sure was quantified (C and D), and
Western blots were performed to show
RhoJ knockdown (E) or ectopic GFP/
GFP-daRhoJ expression (F).
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have been shown to control the actin cytoskeleton and RhoJ
localizes to focal adhesions, experiments were performed to
investigate how RhoJ knockdown might affect both f-actin
and focal adhesion formation.
In initial experiments, HUVECs were either mock-transfected
or transfected with siControl, RhoJ D1, or D2, and after 2 days,
cells were adhered to gelatin-coated coverslips at a low density
and were stained with phalloidin to detect f-actin and with
anti-vinculin antibodies to visualize focal adhesions. The
control-transfected HUVECs generally showed a modest num-
ber of stress fibers and focal adhesions, and the cells had a
number of cellular extensions (supplemental Figure XIIA). In
contrast, cells with reduced RhoJ expression had a more circular
appearance with fewer cell protrusions and increased numbers of
stress fibers, which, in many cells, were observed around the cell
edge. Knockdown of RhoJ also resulted in significantly more
numerous focal adhesions (supplemental Figure XIIB).
Endothelial cells in vessels are normally found as a monolayer
surrounded by other endothelial cells; the exceptions to this are
the endothelial tip cells found at the leading end of an angiogenic
sprout.28 To assess whether RhoJ knockdown differentially
affected f-actin and focal adhesion numbers in endothelial cells
depending on their cellular context, cells at the edge of a scratch
wound at the migration front were compared with those found
within a monolayer. Two days after transfection, a scratch was
made, and the cells were allowed to migrate before they were
fixed and stained with either fluorescently conjugated phalloidin
or anti-vinculin antibodies. siRNA-mediated knockdown of
RhoJ resulted in significantly increased focal adhesion numbers
in cells at the edge of a scratch compared with control-
transfected cells (Figure 4A and 4B); in contrast, no differences
were observed in cells within the monolayer (data not shown).
Figure 4. RhoJ activity affects focal adhesion number in migrating
cells. A, HUVECs were mock-transfected, transfected with siControl
or RhoJ siRNA duplexes (concentration:10 nmol/L), or lentivirally
transduced to express GFP or GFP-daRhoJ; scratch-wound
assays and immunofluorescence using anti-vinculin antibodies
were performed. B, Focal adhesion quantification in cells at the
wound edge.
Figure 3. RhoJ regulates tubule formation. HUVECs were trans-
fected with siControl or RhoJ siRNA duplexes or were mock-
transfected (concentration: 20 nmol/L) (A and B) or lentivirally
transduced to express GFP or GFP-daRhoJ (C and D). HUVECs
were plated on confluent human dermal fibroblasts (HDF) and
after 7 days tubules were stained (A and C). Tubule number,
length, and number of junctions were quantified (B and D).
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RhoJ knockdown did not affect the localization of VE-cadherin
at the cell junctions within the monolayer, suggesting that
cell–cell adhesion is not affected. Lentiviral transduction of
HUVECs with GFP-daRhoJ resulted in slightly faster wound
closure, and enumeration of focal adhesion numbers showed that
overexpression of GFP-daRhoJ resulted in cells at the wound
edge with significantly fewer focal adhesions than the GFP
controls (Figure 4A and 4B). Again no differences were ob-
served in the monolayer. These data indicate a role for RhoJ in
regulating focal adhesion disassembly or turnover.
Similarly, using phalloidin staining of both RhoJ siRNA–
treated HUVECs and HUVECs overexpressing GFP-daRhoJ,
f-actin in cells at the wound edge and in the monolayer was
examined. Whereas no differences were observed in cells in the
monolayer (data not shown), knocking down RhoJ expression
was found to increase the numbers of stress fibers in cells at the
wound edge (Figure 5A). This was quantified by measuring
fluorescence levels in each cell, and significant increases were
found in cells treated with either of the RhoJ-specific duplexes
compared with the controls (Figure 5B). Expression of GFP-
daRhoJ had the opposite effect, significantly reducing levels of
stress fiber in cells at the migration front (Figure 5C and 5D).
Thus, RhoJ may play a role in negatively regulating stress fibers
formation in migrating cells.
The increased actin stress fiber formation may reflect in-
creased actomyosin contractility. Recently, it has been demon-
strated that quiescent tubes have an increased contractility
compared with sprouting tubes, and, indeed, a reduction in
contractility was required to enable endothelial cell sprouting.7
The effect of RhoJ in regulating contractility was measured in 2
ways: by measuring endothelial cell–mediated contraction of a
type I collagen gel and by determining the levels of phospho-
MLC in endothelial cells forming tubes on Matrigel.
An assay previously used to measure endothelial contractility
and traction was performed17; siRNA-transfected HUVECs or
HUVECs expressing GFP/GFP-daRhoJ were imbedded in a
collagen gel. After 2 days, the gels were released from the sides
of the well, and the plates were incubated for a further 5 days,
as the contractility developed within the cells, so the gel
retracted, and the amount of contractility was assessed by
measuring the diameter of the gel. As a control, 5 mol/L
blebbistatin, an inhibitor of nonmuscle myosin II,29 was
added. Knockdown of RhoJ expression with either of the
RhoJ-specific duplexes resulted in a highly significant in-
crease in contraction, which was mostly reversed with bleb-
bistatin. GFP-daRhoJ expression resulted in a small but
significant reduction in the contractility compared with cells
expressing GFP alone (Figure 5E). Knockdown of RhoJ was
also associated with increased phospho-MLC in HUVECs
plated on Matrigel, indicating that these cells have increased
actomyosin contractility (Figure 5F). No differences were
seen in the levels of phospho-MLC as a result of expressing
GFP-daRhoJ.
Collectively, these data suggest that RhoJ may be involved
in promoting endothelial cell motility and tube formation by
negatively regulating MLC phosphorylation and reducing
actomyosin contractility. In this case, pharmacological inhi-
bition of ROCK, a kinase that catalyzes MLC phosphoryla-
tion,5 should reverse the impaired motility and tube formation
induced by RhoJ knockdown. Indeed, we found that the
ROCK inhibitor Y27632, when added to RhoJ siRNA–treated
endothelial cells, restored motility both in the scratch-wound
assay (Figure 6A and 6B) and Boyden chamber chemotaxis
assay (supplemental Figure XIII). RhoJ knockdown cells
migrated to close the scratch when treated with the ROCK
inhibitor at a similar rate to that of the negative control duplex
treated cells (Figure 6A and 6B). Additionally, ROCK inhi-
bition restored the impaired tube formation on Matrigel of
RhoJ siRNA–transfected cells, resulting in a more connected
and stable tube formation, equivalent to that seen in the
negative control duplex–treated cells (Figure 6C and 6D).
Addition of 10 mol/L ROCK inhibitor Y27632 resulted in
reduction in phospho-MLC in all samples (supplemental
Figure XIV). Similar data were obtained with a structurally
unrelated ROCK inhibitor H1152, with the other RhoJ siRNA
duplex D1 (data not shown) and with 5 mol/L blebbistatin,
a myosin II inhibitor (supplemental Figures XV and XVI).
These data strongly suggest that RhoJ is a negative regulator
of actomyosin contractility.
Figure 5. RhoJ influences stress fibers
and actomyosin contractility. HUVECs
were transfected with siControl, RhoJ
siRNA duplexes or mock-transfected
(concentration: 10 nmol/L) (A, B, E, and
F) or lentivirally transduced to express
GFP or GFP-daRhoJ (C through E),
scratch-wound assays were performed,
and f-actin was visualized (A and C) and
quantified (B and D). Contractility was
measured by collagen gel contraction (E)
or phospho- and total MLC blotting (F).
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Discussion
These data are the first to determine the intracellular local-
ization of RhoJ, demonstrate endothelial expression in tis-
sues, show activation by VEGF, and identify a pivotal role for
this Rho GTPase RhoJ in endothelial cell motility, tube
formation, and modulation of the actin cytoskeleton and focal
adhesion formation.
Previous bioinformatic and primary cell line expression
studies performed by our laboratory identified RhoJ as having
an endothelial specific mRNA expression pattern.9 In this
present study, we have demonstrated expression by endothe-
lial cells in vessels in a number of tissues and cancer types,
although it is absent from brain vessels and from normal and
cancerous tissue of the digestive tract. We also demonstrate a
vascular expression pattern of RhoJ in the mouse embryo, at
a stage in development when angiogenesis is occurring. This
expression pattern suggests that it plays a role in the normal
functioning of endothelial cells in a number of tissues, as well
as potentially in angiogenesis. Although expression levels of
RhoJ are high in endothelial cells, we have observed low
levels of expression in nonendothelial cell types, indicating
that expression of RhoJ is not restricted to endothelial cells.
The function of RhoJ in endothelial cells was probed by
using both siRNA-mediated knockdown of RhoJ expression
and expression of a constitutively active form of RhoJ, locked
into its GTP-bound form. As expected, these 2 approaches
gave contrasting phenotypes. Knockdown of RhoJ resulted in
impaired migration and tube formation, whereas daRhoJ
promoted motility and excessive sprouting during tube for-
mation. Knocking down RhoJ expression using siRNA du-
plexes impaired cell migration and reduced proliferation,
processes involved at early time points in the formation of
tubules in the organotypic model. In addition, the RhoJ
siRNA–induced increased contractility would have also been
likely to be detrimental to tube formation, because previously
increased actomyosin contractility resulted in cell detachment
and cell death in this model of tubule formation.6 In contrast,
the chaotic appearance of the tubules observed with the
daRhoJ is reminiscent of abnormal, sprouting endothelium, a
process dependent on VEGF receptor 2.30 The use of the
organotypic assay enabled the identification of a role for
RhoJ in tubulogenesis in a physiological setting; however, we
are unable to conclude downstream of which soluble or extra-
cellular matrix factor RhoJ is acting in this system. Knocking
down RhoJ did not affect the expression of the other major Rho
GTPases, RhoA, Rac1, or Cdc42, and we conclude that RhoJ is
playing a distinct role in endothelial cells.
To understand the molecular mechanisms by which RhoJ
was acting, the effect of modulating its activity on focal
adhesions numbers and contractility was investigated. Reduc-
ing the activity of RhoJ resulted in increased numbers of focal
adhesion and stress fibers in cells migrating at the edge of
scratch; additionally, we observed an increase in the physical
contractility, as measured by the contraction of a collagen gel.
Expressing daRhoJ again gave the converse phenotype.
Interestingly, the stress fiber and focal adhesion phenotype
was only evident in migrating cells, either plated sparsely or
at a scratch-wound edge, and not in cells within a monolayer.
This suggests that RhoJ plays a critical role in migrating cells,
whereas in cells within a monolayer, the effects of modulat-
ing RhoJ expression may be inhibited through signaling from
neighboring cells. This lack of phenotype observed in the
monolayer may explain why siRNA-mediated downregula-
tion of RhoJ did not inhibit early wound closure (Figure 2A
and 2C), with the accumulation of focal adhesions and f-actin
occurring only after the cells had started to move and had
reduced contact with neighboring cells.
We have additionally demonstrated that RhoJ knockdown
results in an increase in MLC phosphorylation. MLC can be
phosphorylated by a number of kinases including RhoA-
dependent ROCK and Ca2-dependent MLC kinase, which
result in increased myosin ATPase activity and increased
stress fiber contractility.31 Using 2 structurally unrelated
inhibitors of ROCK or an inhibitor of nonmuscle myosin II,
Figure 6. Inhibition of ROCK restores migration and tube forma-
tion in RhoJ siRNA–treated HUVECs: scratch-wound (A) and
Matrigel (C) assays were set up 2 days after transfection with
siControl or RhoJ D2 (concentration: 10 nmol/L), with or without
addition of ROCK kinase inhibitor Y27632. These assays were
quantified (B and D).
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the motility defect of RhoJ siRNA–treated endothelial cells
was reversed in both the scratch-wound and Matrigel tube-
forming assays. There is evidence that reduced contractility is
required for endothelial sprouting to occur,6,7 and our data
suggest that RhoJ may play a role in this process.
At present, we do not know the molecular basis by which
RhoJ affects contractility and focal adhesion numbers. There
is a complex interplay and reciprocal regulation between
focal adhesion maturation, turnover, and actomyosin contrac-
tility; thus, components of focal adhesions have been shown
to regulate contractility, and, conversely, modulating myosin
II activity can influence focal adhesion size and distribution.32
Thus, RhoJ may regulate actomyosin contractility via dy-
namic regulation of focal adhesions.
This hypothesis is consistent with the localization of endog-
enously expressed RhoJ to focal adhesions. Previously, only
localization of overexpressed RhoJ to early and recycling endo-
somes had been reported,16 and, indeed, we have observed the
same. Because overexpressing proteins can often drive aberrant
localization, we developed a purified polyclonal antiserum that,
unlike the commercially available anti-RhoJ monoclonal anti-
bodies, recognized endogenous RhoJ. Because a role for RhoJ in
early endocytic recycling has been reported, we investigated
whether RhoJ knockdown affected surface levels of VEGF
receptor 2 either in resting cells or after VEGF stimulation; in
neither case were any differences noted (data not shown).
In conclusion, we have identified RhoJ as a new player in
endothelial cell biology. We have demonstrated that this
endothelial-expressed Rho GTPase is activated by VEGF and
is able to modulate actomyosin contractility and focal adhe-
sion assembly. It plays a critical role in endothelial cell
motility and tube formation and will likely prove to be a key
player in angiogenesis in vivo.
Acknowledgments
We acknowledge Dr Michael Tomlinson for critical reading of the
manuscript and Sharon Timms and Dr Zsuzsanna Nagy for devel-
oping the fluorescent in situ hybridization method.
Sources of Funding
This work was supported by the British Heart Foundation, Cancer
Research UK, and University of Birmingham College of Medical
and Dental Sciences.
Disclosures
None.
References
1. Heath VL, Bicknell R. Anticancer strategies involving the vasculature.
Nat Rev Clin Oncol. 2009;6:395–404.
2. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lym-
phangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464–478.
3. Bryan BA, D’Amore PA. What tangled webs they weave: Rho-GTPase
control of angiogenesis. Cell Mol Life Sci. 2007;64:2053–2065.
4. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;
116:167–179.
5. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour.
Nat Rev Mol Cell Biol. 2003;4:446–456.
6. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R,
Bird D, Marshall CJ. ERK-MAPK signaling opposes Rho-kinase to
promote endothelial cell survival and sprouting during angiogenesis.
Cancer Cell. 2006;9:33–44.
7. Abraham S, Yeo M, Montero-Balaguer M, Paterson H, Dejana E,
Marshall CJ, Mavria G. VE-Cadherin-mediated cell-cell interaction sup-
presses sprouting via signaling to MLC2 phosphorylation. Curr Biol.
2009;19:668–674.
8. Legate KR, Wickstrom SA, Fassler R. Genetic and cell biological anal-
ysis of integrin outside-in signaling. Genes Dev. 2009;23:397–418.
9. Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R. A novel
method of differential gene expression analysis using multiple cDNA
libraries applied to the identification of tumour endothelial genes. BMC
Genomics. 2008;9:153.
10. Chiang SH, Hou JC, Hwang J, Pessin JE, Saltiel AR. Cloning and
functional characterization of related TC10 isoforms, a subfamily of Rho
proteins involved in insulin-stimulated glucose transport. J Biol Chem.
2002;277:13067–13073.
11. Vignal E, De Toledo M, Comunale F, Ladopoulou A, Gauthier-Rouviere
C, Blangy A, Fort P. Characterization of TCL, a new GTPase of the rho
family related to TC10 andCcdc42. J Biol Chem. 2000;275:36457–36464.
12. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of
glucose transport. Mol Med. 2004;10:65–71.
13. Abe T, Kato M, Miki H, Takenawa T, Endo T. Small GTPase Tc10 and
its homologue RhoT induce N-WASP-mediated long process formation
and neurite outgrowth. J Cell Sci. 2003;116:155–168.
14. Aspenstrom P, Fransson A, Saras J. Rho GTPases have diverse effects on
the organization of the actin filament system. Biochem J. 2004;377:
327–337.
15. Nishizuka M, Arimoto E, Tsuchiya T, Nishihara T, Imagawa M. Crucial
role of TCL/TC10beta L, a subfamily of Rho GTPase, in adipocyte
differentiation. J Biol Chem. 2003;278:15279–15284.
16. de Toledo M, Senic-Matuglia F, Salamero J, Uze G, Comunale F, Fort P,
Blangy A. The GTP/GDP cycling of rho GTPase TCL is an essential
regulator of the early endocytic pathway. Mol Biol Cell. 2003;14:
4846–4856.
17. Vernon RB, Sage EH. Contraction of fibrillar type I collagen by endo-
thelial cells: a study in vitro. J Cell Biochem. 1996;60:185–197.
18. Piette D, Hendrickx M, Willems E, Kemp CR, Leyns L. An optimized
procedure for whole-mount in situ hybridization on mouse embryos and
embryoid bodies. Nat Protoc. 2008;3:1194–1201.
19. Holthofer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen
A. Ulex europaeus I lectin as a marker for vascular endothelium in human
tissues. Lab Invest. 1982;47:60–66.
20. Walls JR, Coultas L, Rossant J, Henkelman RM. Three-dimensional
analysis of vascular development in the mouse embryo. PLoS One.
2008;3:e2853.
21. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev
Biochem. 1998;67:395–424.
22. Clemens MJ. Translational control in virus-infected cells: models for
cellular stress responses. Semin Cell Dev Biol. 2005;16:13–20.
23. Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N,
Gongora C. The exonuclease ISG20 is directly induced by synthetic dsRNA
via NF-kappaB and IRF1 activation. Oncogene. 2004;23:4636–4640.
24. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN. An in
vitro model of angiogenesis: basic features. Angiogenesis. 1999;3:335–344.
25. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in
vitro human ‘angiogenesis’ assays with capillaries formed in vivo. Angio-
genesis. 2001;4:113–121.
26. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev
Cancer. 2002;2:795–803.
27. Garrett TA, Van Buul JD, Burridge K. VEGF-induced Rac1 activation in
endothelial cells is regulated by the guanine nucleotide exchange factor
Vav2. Exp Cell Res. 2007;313:3285–3297.
28. Adams RH, Eichmann A. Axon guidance molecules in vascular pat-
terning. Cold Spring Harb Perspect Biol. 2010;2:a001875.
29. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR,
Mitchison TJ. Dissecting temporal and spatial control of cytokinesis with
a myosin II Inhibitor. Science. 2003;299:1743–1747.
30. Jain RK. Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science. 2005;307:58–62.
31. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle
myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol
Cell Biol. 2009;10:778–790.
32. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating
cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;
11:633–643.
664 Arterioscler Thromb Vasc Biol March 2011
 at University of Birmingham (bhm) / England on June 16, 2011 atvb.ahajournals.orgDownloaded from 
Supplement Material 
 
RhoJ/TCL regulates endothelial motility and tube formation and modulates 
actomyosin contractility and focal adhesion numbers 
 
Sukhbir Kaur, Katarzyna Leszczynska, Sabu Abraham, Margherita Scarcia, Sabina 
iltbrunner, Christopher J Marshall, Georgia Mavria, Roy Bicknell and Victoria L. Heath H
 
 
 at University of Birmingham (bhm) / England on June 16, 2011 atvb.ahajournals.orgDownloaded from 
Adrenal
Colon
Heart Liver Lymph node
Bladder CAMuscle
Pancreas
Stomach Brain Ovarian CA
Lung
R
ho
J
U
le
x
R
ho
J 
/ U
le
x
R
ho
J
U
le
x
R
ho
J 
/ U
le
x
Figure I: Tissue distribution of RhoJ expression
Fluorescence in situ
 
hybridisation
 
was performed on a variety of normal and cancerous 
human tissue sections using digoxigenin
 
labelled
 
RhoJ specific riborprobe
 
(red) and Ulex
 
europeaus
 
agglutinin I to stain the endothelial cells
 
(green).  Nuclei were stained using DAPI 
(blue).  Erythrocytes which are found in vessels in some tissue sections autofluoresce
 
in both 
the red and green channels.  Scale bar represents 20 µm.
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Figure II: RhoJ is expressed at low levels in pericytes
 
and aortic smooth muscle cells
A RNA was isolated from human umbilical vein endothelial cells (HUVEC), human aortic 
smooth muscle cells (HASMC) and pericytes
 
isolated from human placenta (hPC-PL).  
Reverse transcription and probe-based quantitative PCR was undertaken to determine levels 
of RhoJ and β-actin expression. The graph shows expression of RhoJ normalised
 
to β-actin 
expression.  The numbers show the values.  B Cellular extract from HUVEC, HASMC and 
hPC-PL were subjected to SDS-PAGE and western blotting with anti-RhoJ and anti-tubulin
 
antibodies.  This experiment was performed on single isolates of
 
each cell type.
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Figure III: The anti-RhoJ monoclonal and rabbit polyclonal antibodies do not detect 
Cdc42, RhoA
 
or Rac1 by western blotting
Embryonic kidney HEK293 cells, which do not express RhoJ, were transfected
 
with 
plasmids in order to express myc-(da)RhoA, flag-Cdc42, HA-Rac1, as well as RhoJ tagged 
with the same epitopes.  Lysates
 
were prepared, subjected to SDS-PAGE and western blotted 
with different antibodies as indicated.  The epitope
 
tagged RhoA, Cdc42 and Rac1 were not 
detected by either the monoclonal or rabbit polyclonal anti-RhoJ antibodies.  This 
experiment was performed once.
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Figure IV: Knockdown of RhoJ expression does not alter expression of RhoA, Cdc42 or 
Rac1
HUVEC were either mock transfected
 
or transfected
 
with siControl
 
or RhoJ siRNA duplexes 
D1 or D2 at 25 nM. Two days after transfection, cells were harvested, lysed
 
and subjected to 
SDS-PAGE and western blotting for RhoJ, RhoA, Cdc42, Rac1 or tubulin.  This is 
representative of data from three experiments.
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Figure V: Expression and localisation
 
of GFP-daRhoJ
HUVEC were transduced
 
with lentivirus
 
to express either GFP or GFP-daRhoJ, GFP positive 
cells were purified by flow cytometric
 
sorting.  A
 
Western blots of lysates
 
from HUVEC 
expressing either GFP or GFP-daRhoJ, blotted for GFP, RhoJ or tubulin. B
 
Cells were plated 
and immunofluorescence with anti-vinculin
 
antibody was performed to visualise
 
the focal 
adhesions.  The nuclei were stained with DAPI.  The region in the white box is expanded to 
give a more detailed view of these areas of the cell.  GFP-daRhoJ
 
localised
 
to the membrane 
where it is concentrated in focal adhesions (white arrows) as well as being found in intracellular 
vesicles (yellow arrows).  These data are representative of three experiments.
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AB
Figure VI: RhoJ regulates endothelial cell growth, survival and chemotaxis
HUVEC were either mock transfected
 
or transfected
 
with siControl, RhoJ D1 or RhoJ D2 siRNA 
duplexes at 10 nM. A
 
Cell growth was assessed by cell counting each day after transfection.  Error 
bars represent the standard error of the triplicates for each time point. B
 
Three days after 
transfection, cells were stained with Annexin
 
V and Propidium
 
iodide (PI) and analysed
 
by a 
Fluorescence Activated Cell Scanner. The percentage of cells stained double positive for both 
Annexin
 
V and propidium
 
iodide is indicated.  These data are representative of three experiments. 
C
 
Two days after transfection, a Boyden chamber chemotaxis assay was performed and the number
 
of migrated cells quantified. The error bars represent the standard error of the mean, RhoJ 
knockdown with either RhoJ D1 or RhoJ D2 resulted in a highly significant reduction in chemotaxis 
( *** p < 0.0001 comparing RhoJ D1 or RhoJ D2 with siControl
 
using a Mann-Whitney Test).
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BFigure VII: RhoJ mediates 2-dimensional endothelial tube formation on matrigel
A
 
HUVEC were either mock transfected
 
or transfected
 
with siControl
 
or RhoJ siRNA 
duplexes D1 or D2 at 10 nM. Two days after transfection, cells were plated on to matrigel
 
and 
incubated for a further 24 hours. Pictures were taken at 10 and 24 hours. Scale bar represents 
200 μm. B
 
The matrigel
 
assays were quantified by counting the number of nodes with 1, 2, 3 
or 4 branchpoints
 
from five fields of view from one representative experiment.  The mean 
number of nodes per field is shown and error bars represent standard error of the mean.  These 
data are representative of three experiments.
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Figure VIII: Analysis of RhoJ knockdown at 3 –
 
6 days post transfection
HUVEC were transfected
 
with siControl
 
or RhoJ siRNA duplexes D1 or D2 at 20 nM
 
using 
Genefector
 
reagent. Cells were harvested at days 3, 4, 5 and 6 after transfection, lysates
 
prepared and protein concentrations determined.  10 µg of protein extract per sample was 
subjected to SDS-PAGE and western blotting with anti-RhoJ and anti-tubulin
 
antibodies.  
Densitometry of this blot demonstrates that for RhoJ D1 and D2 there was approximately 
60% and 40% knockdown of RhoJ, respectively, persisting at 4 days after transfection.
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Figure IX: Knockdown of RhoJ reduces endothelial motility in the
 
microvascular
 
cell 
line HMEC-1 
A
 
HMEC-1 cells were either mock transfected
 
or transfected
 
with negative control duplex 
(siControl), RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM.  A scratch was made two 
days after transfection
 
and the scratch was imaged at time 0, 4, 12 and 24 hours.  Scale bar 
represents 200 μm. B
 
Quantitation
 
of the wound closure.  This experiment was performed 
once with this endothelial cell line.
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Figure X: RhoJ regulates 2-dimensional tube formation in a microvascular
 
cell line 
HMEC-1 
A
 
HMEC-1 were either mock transfected
 
or transfected
 
with the siControl
 
or RhoJ siRNA 
duplexes D1 or D2 at 10 nM. Two days after transfection, cells were plated on to matrigel
 
and 
incubated for a further 24 hours. Pictures were taken at 10 and 24 hours. Scale bar represents 
200 μm. B
 
The matrigel
 
assays were quantified by counting the number of nodes with 1, 2, 3 
or 4 branchpoints
 
from five fields of view from one representative experiment.  The mean 
number of nodes per field is shown and error bars represent standard error of the mean. This 
experiment was performed once with this endothelial cell line.
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Figure XI: RhoJ and Cdc42 are activated by VEGF-A in HUVEC 
HUVEC were stimulated with VEGF-A (10 ng/ml) for the times indicated. Active RhoJ 
(GTP-RhoJ) or Cdc42 (GTP-Cdc42) were determined by pull-down (PD) with GST-PBD and 
western blotting.  The whole cell lysates
 
(WCL) were blotted as a loading control.  
Densitometry was performed on these western blots and amount of activated RhoGTPase
 
plotted relative to total RhoGTPase, with the zero time point normalized to 1.  The graphs 
show the mean and standard error of the mean derived from 5 experiments using different 
donors.  Using the Wilcoxon
 
signed-rank test all time points for Cdc42 and the 15 minute 
time point for RhoJ were statistically significant (p<0.05), these are indicated by an *.
*
*
* * *
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Figure XII: Knocking down RhoJ expression increases stress fibres, focal adhesions and 
actomyosin contractility
A HUVEC were transfected
 
with RhoJ D1, RhoJ D2, siControl
 
siRNA at 10 nM
 
or mock 
transfected. Two days after transfection, cells were plated at low density on to gelatin
 
coated 
coverslips
 
and stained to visualise f-actin (phalloidin) and focal adhesions (anti-vinculin). This 
data is representative of three experiments.  Scale bar represents 20 µm.  B The number of focal 
adhesions per cell was quantified for 30 cells from 3 experiments and displayed as a box and 
whisker plot, this indicates the maximum, minimum, 25th
 
and 75th
 
percentiles and median 
values.  Focal adhesion number was significantly increased by RhoJ knockdown (p < 0.001 
comparing D1 or D2 with siControl
 
using a Mann Whitney test).
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Figure XIII: Inhibition of ROCK restores chemotaxis in RhoJ siRNA treated 
HUVEC
HUVEC were transfected
 
with either 10n M siScramble
 
or RhoJ D2. A Boyden chamber 
chemotaxis assay was set up two days later at which point groups
 
were divided and 
treated either with (+Y) or without ROCK kinase inhibitor Y27632.   The number of 
migrated cells were quantified. The error bars represent the standard error of the mean, 
*** p = 0.0006 comparing RhoJ D2 with RhoJ D2 + Y27632 using a Mann Whitney 
test.  Scale bar represents 200 μm.
***
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Figure XIV: Inhibition of ROCK reduces phospho-MLC in both control HUVEC and 
HUVEC with reduced RhoJ expression
HUVEC were transfected
 
with RhoJ D1, RhoJ D2, siControl
 
at 10 nM
 
or mock transfected. 
One day after transfection, cells were replated
 
on matrigel
 
either with or without the ROCK 
kinase inhibitor Y27632 at 10 µM, after 24 hours cell lysate
 
was prepared and blotted for 
phospho and total MLC.  This experiment was performed once.
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Figure XV: Inhibition of non-muscle myosin restores migration in RhoJ siRNA treated 
HUVEC
HUVEC were transfected
 
with either siControl, RhoJ D1 or RhoJ D2 at 10 nM.  Assays were 
set up two days later at which point groups were divided and treated either with (+Bleb) or 
without the non-muscle myosin inhibitor blebbistatin
 
at 5 µM. These data are representative 
of three experiments.  A The Scratch wound assay was performed and the cells were 
visualised
 
at 0, 4, 12 and 24 hours. Scale bar represents 200 μm. B The percentage wound 
closure was measured for three independent experiments and plotted, error bars represent the 
standard error of the mean.
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Figure XVI: Inhibition of non-muscle myosin restores tube formation in RhoJ siRNA 
treated HUVEC
HUVEC were transfected
 
with either siControl, RhoJ D1 or RhoJ D2 at 10 nM.  Assays were 
set up two days later at which point groups were divided and treated either with (+Bleb) or 
without the non-muscle myosin inhibitor blebbistatin
 
at 5 µM. A
 
Cells were plated on to 
matrigel
 
and images taken 10 and 24 hours later. Scale bar represents 200 μm.  B
 
The matrigel
 
assays were quantified by counting the the
 
number of nodes with 1, 2, 3 or 4 branchpoints
 
from 
five fields of view from one representative experiment.  The mean number of nodes per field is 
shown and error bars represent standard error of the mean.
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Full legends 
 
Figure 1: RhoJ has a vascular expression pattern  
A Fluorescent in situ hybridization on a human tissue sections using digoxigenin labelled 
riboprobes/anti-digoxigenin-rhodamine (red) in combination with Ulex europeaus agglutinin I- 
fluorescein (green).  B Whole-mount in situ hybridization experiments were performed on E9.5 
mouse embryos using full length mouse RhoJ antisense and sense riboprobes. Von Willebrand 
Factor (VWF) riboprobes were also used as a positive control for endothelial cell expression. 
There is a magnified image of both the sense and antisense hybridization; white arrows indicate 
the intersomitic vessels and the yellow arrows mark the dorsal aorta.  This is representative of 
three experiments.  C Immunofluorescence staining of HUVEC using anti-mouse RhoJ (green) 
and anti-vinculin or anti-phospho-FAK (Y397) (red). Nuclei were counterstained with DAPI.   
There is a magnified image showing co-localisation.  This was repeated with at least three 
different isolates of HUVEC. 
 
Figure 2: RhoJ regulates endothelial cell motility  
A, C, E  HUVEC were either mock transfected or transfected with siControl or RhoJ siRNA 
duplexes D1 or D2 at 10 nM. A Two days after transfection, scratches were made and the cells 
visualised at 0, 4, 12 and 24 h. C The percentage of the wound remaining at different time points 
was measured from three independent experiments and the mean plotted with error bars denoting 
the standard error.  Statistically significant differences were observed at the 24 hour time point 
by comparing RhoJ D1 and D2 transfected cells with the siScramble control transfected cells by 
the Student T test (** p= 0.001 to 0.01 and * p=0.01 to 0.05.) E  Western blot of transfected 
HUVEC was performed using anti-RhoJ and anti-tubulin antibodies to demonstrate RhoJ 
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knockdown. B, D, F  HUVEC were transduced with lentivirus and and sorted to generate 
populations of HUVEC expressing either GFP (control) or GFP-daRhoJ.  Scratch wound assays 
were performed and the cells visualised at 0, 4, 8 and 12 h. D The percentage of the wound 
remaining at different time points was measured from three independent experiments and the 
mean plotted with error bars denoting the standard error.  F A western blot using anti-GFP 
antibodies to show expression of GFP and GFP-daRhoJ.  These data are representative of three 
experiments. 
 
Figure 3: RhoJ mediates endothelial tube formation 
A, B RhoJ knockdown inhibits tubule formation.  HUVEC were either mock transfected or 
transfected with siControl or RhoJ siRNA duplexes D1 or D2 at 20 nM.  A day after transfection 
they were seeded on to confluent HDF and cultured for a further 5 days to allow tubules to 
develop, these were visualised by staining with anti-CD31.  B Tubule length, number and the 
number of junctions were quantified using the AngioSys software from at least 9 fields of view, 
all were highly significantly reduced as a result of RhoJ knockdown (p < 0.001 comparing RhoJ 
D1 or RhoJ D2 with siControl using a Mann Whitney test). C, D Expression of GFP-daRhoJ 
promotes tubule sprouting.  HUVEC were transduced with lentivirus to express GFP or GFP-
daRhoJ and GFP positive cells were purified by cell sorting.  These were then plated on HDF as 
described above.  D Total tubule length, mean tubule length, tubule number and the number of 
junctions per field were quantified using the Angiosys software.  Data plotted represent the mean 
of 9 fields and error bars represent the standard error.  Expression of daRhoJ increased the 
number of junctions and tubules compared with the GFP control, but resulted in a reduction in 
the mean tubule length (using a Mann Whitney test comparing control GFP were compared with 
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GFP-daRhoJ, *** p<0.001, ** p= 0.001 to 0.01 and * p=0.01 to 0.05.)  These data are 
representative of three experiments. 
 
Figure 4: RhoJ activity regulates focal adhesion number 
A  HUVEC were transfected with RhoJ D1, RhoJ D2, siControl siRNA at 10 nM duplex or mock 
transfected or lentivirally transduced to express GFP or GFP-daRhoJ.   Scratch wound assays 
were set up, cells were allowed to migrate, and were then fixed and focal adhesions visualised 
using anti-vinculin immunofluorescence.  These data are representative of three experiments.     
B Focal adhesion numbers in cells at the scratch margin were quantified for at least 20 cells from 
3 experiments and displayed as a box and whisker plot, this indicates the maximum, minimum, 
25th and 75th percentiles and median values.  Focal adhesion number was significantly increased 
by RhoJ knockdown and significantly decreased by expression of GFP-daRhoJ (p < 0.001 
comparing RhoJ D1 or RhoJ D2 with siControl and also by comparing GFP with GFP-daRhoJ 
using a Mann Whitney test).  
 
Figure 5: RhoJ influences stress fibres and actomyosin contractility.  HUVEC were 
transfected with RhoJ D1, RhoJ D2, siControl siRNA duplex at 10 nM or mock transfected (A, 
B, E, F) or lentivirally transduced to express GFP or GFP-daRhoJ (C, D, E).   A, C Scratch 
wound assays were set up and the cells allowed to migrate, cells were then fixed and f-actin 
visualised by staining with phalloidin-TRITC.  These data are representative of three 
experiments.  B, D The fluorescence intensity/cell in cells at the wound edge was quantified 
from at least 20 cells from 3 experiments and displayed as a box and whisker plot, this indicates 
the maximum, minimum, 25th and 75th percentiles and median values.  The fluorescence/cell was 
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significantly increased by RhoJ knockdown and significantly decreased by expression of GFP-
daRhoJ (p < 0.001 comparing RhoJ D1 or RhoJ D2 with siControl and also by comparing GFP 
with GFP-daRhoJ using a Mann Whitney test).  E Collagen gel contraction assays were set up 
using siRNA duplex transfected HUVEC or lentivirally transduced HUVEC as noted above, for 
both the siRNA and lentiviral transduction, three different donor HUVEC were used.  For each 
condition a control was added where the non-muscle myosin II was inhibited by blebbistatin at 5 
µM.  The mean of data from each donor is plotted and error bars represent the standard error, 
pairs of data were compared with a Student T test as indicated *** p<0.001, ** p= 0.001 to 0.01 
and * p=0.01 to 0.05.   F  One day after transfection with siRNA duplexes, cells were replated on 
matrigel, after 24 hours cell lysates were prepared and blotted for phospho- and total MLC.  
Increased phopho-MLC (p-MLC) in RhoJ siRNA treated cells was observed in three 
experiments.  
 
Figure 6: Inhibition of ROCK restores migration and tube formation in RhoJ siRNA 
treated HUVEC 
HUVEC were transfected with either siControl or RhoJ D2 at 10 nM.  Assays were set up two 
days later at which point groups were divided and treated either with or without 10 µM Y27632, 
a ROCK kinase inhibitor.   A Scratch wound assays were performed and the cells were 
visualised at 0, 4, 12 and 24 hours. B The percentage of the wound remaining at different time 
points was measured from three independent experiments and the mean plotted with error bars 
denoting the standard error.  Using the student T test, statistically significant differences were 
observed at the 12 hour time between the untreated siScramble and untreated RhoJ D2 
transfected cells as well as between the RhoJ D2 transfected HUVEC treated with and without 
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Y27632.  At 24 hours, significant differences were observed between the untreated RhoJ D2 
transfected HUVEC and all the other groups (** p= 0.001 to 0.01 and * p=0.01 to 0.05). C Cells 
were plated on to matrigel and images taken 10 and 24 hours later.  D Tube formation at 10 
hours and 24 hours after plating was quantified by counting the number of nodes with 1, 2, 3 or 
≥4 branch-points from five fields of view from each condition at 10 and 24 hour time points.  
Error bars represent standard error of the mean.  These data are representative of three 
experiments. 
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1 Cell lines and culture 
Human umbilical vein endothelial cells (HUVEC) were used between passage 1 and 6 for all 
experiments.  Umbilical cords were obtained from either TCS CellWorks or Birmingham 
Women's Health Care NHS Trust after delivery; mothers had given informed consent. HUVEC 
were cultured to confluence in Media 199 (Sigma) containing 4 mM L-glutamine (Sigma), 90 
μg/ml heparin (Sigma), 10% (v/v) fetal bovine serum (PAA, The Cell Culture Co) supplemented 
with either purified bovine brain extract 1 or large vessel endothelial growth supplements (TCS 
CellWorks). Cells were plated in sterile culture dishes that had been coated with 0.1% (w/v) 
gelatin diluted in phosphate buffered saline (PBS). The plates were incubated in a humidified 
atmosphere with 5% CO2 at 37°C. HUVEC were split at a ratio of 1:3 once a week and were 
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used between passages 1 to 6.  The human microvascular endothelial cell line-1 (HMEC-1) 2 was 
cultured in the same way as HUVEC.  Human pericytes from human placenta (hPC-PL) were 
obtained from Promocell and cultured in Pericyte Growth Medium (Promocell) on untreated 
tissue culture plastic, and used between passage 2-4.  Human aortic smooth muscle cell lines 
(HASMC) were purchased from TCS Cell Works and cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 4 mM L-glutamine (Sigma), Pencillin Streptomycin 
Solution (Sigma) and 10% (v/v) fetal bovine serum (PAA, The Cell Culture Co).  These were 
also cultured on untreated tissue culture plastic and used between passages 2-4.  Lentivirus was 
produced using human embryonic kidney (HEK) 293T cells as the packaging cell line.  These 
cells were cultured as for the HASMC. 
 
2 Antibodies and pharmacological inhibitors 
Primary antibodies used were as follows: anti-GFP (3E1 clone, CRUK), anti-RhoA (Santa Cruz 
Biotechnology), anti-Rac1 (Millipore) anti-RhoJ (Abcam), anti-Tubulin (Sigma), anti-Cdc42 
(BD Biosciences), anti-vinculin (Sigma), anti-VE cadherin (eBioscience), phospho-MLC2 
(thr18/ser19,  New England Biolabs) and pan MLC2 (Santa-Cruz).  The production of the 
purified rabbit anti-RhoJ polyclonal antisera is described in Section 23 below.  Secondary 
antibodies were anti-mouse immunoglobulin Alexa-fluor 488 (Invitrogen), anti-mouse 
immunoglobulin Alexa-fluor 546 (Invitrogen), polyclonal goat anti-mouse immunoglobulins - 
horseradish peroxidase (HRP) (Dako Cytomation), and polyclonal goat anti-rat immunoglobulin 
conjugated to HRP (Sigma) and HRP-conjugated anti-rabbit immunoglobulin. Filamentous actin 
was visualized using phalloidin-TRITC (Invitrogen).  The ROCK inhibitor Y27632 (Tocris) was 
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used at a concentration of 10 µM and the non-muscle myosin II inhibitor blebbistatin (Tocris) 
was used at 5 µM.  
 
3 Plasmids 
pGEX KG-PBD was used to produce glutathione S-Transferase – Pak1 p21-binding domain 
(GST-PBD, the PBD encoded amino acids 1-254 of Rattus norvegicus PAK1 which 
encompasses the CRIB domain).  In order to produce recombinant fusion protein for production 
and purification of RhoJ specific antisera, wild type RhoJ lacking the sequence encoding the 
CAAX box was cloned into the BamHI and HindIII restriction sites of pMAL2CE and BamHI 
and SmaI restriction sites of pGEX 4T2. 
 
Riboprobes were synthesized from plasmids pGEM3Z-mRhoJ (mouse RhoJ 1-645 of coding 
region), pGEM3Z-mVWF (7838-8387 of coding region) and pGEM3Z-hRhoJ (human RhoJ 1-
645 of coding region).  Mouse RhoJ (1-645 of coding region) was cloned into pGEM-3z using 
5’-EcoR1 and 3’HindIII restriction sites. Mouse von Willebrand Factor (VWF) (7838-8387 of 
coding region) was cloned into pGEM-3z plasmid using 5’-BamH1 and 3’-EcoR1 restiction 
sites. Human RhoJ (1-645 of coding region) was cloned into pGEM-3z plasmid using 5’-BamH1 
and 3’-EcoR1 restriction sites.   
 
The plasmids used for lentivirus production were pWPI (a lentiviral mammalian expression 
vector with an EMCV IRES-EGFP cassette; Addgene) or pWPXL-GFP-daRhoJ (see below) in 
combination with plasmids psPAX2 (Lentiviral packaging for mammalian expression; Addgene) 
and pMD2G (Envelope plasmid; Addgene). To generate lentivirus for expressing GFP-daRhoJ, 
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the constitutively active RhoJ mutant (Q79L) coding sequence was firstly cloned pEGFP-C1 
using HindIII and EcoRI restriction sites (forward primer 5’-
tagtagaagctttgatgaactgcaaagagggaactgac-3’, reverse primer 5’- 
tagtagaagcttgaattctcagataattgaacagcagctgtg-3’) to generate daRhoJ tagged at the N terminus with 
GFP. Then the GFP-daRhoJ fragment was amplified from pEGFP-C1-daRhoJ (forward primer 
5’- tagtagggatccgccaccatggtgagcaagggc-3’, reverse primer 5’- 
tagtagaagcttgaattctcagataattgaacagcagctgtg-3’) and cloned into pWPXL (lentiviral mammalian 
EGFP expression plasmid; Addgene) using BamHI and EcoRI restriction sites such that the 
GFP-daRhoJ replaced the existing EGFP insert.     
 
Expression plasmids for expressing epitope tagged RhoA, Rac1, Cdc42 and RhoJ were as 
follows: pRK5-FLAG-Cdc42, pRK5-HA-Rac, pRK5-myc-V14RhoA and pEF6A-myc-RhoJ, 
pEF6A-HA-RhoJ and pEF6A-FLAG-RhoJ.  
 
4 siRNA transfection 
For siRNA experiments the duplexes were as follows: RhoJ siRNA duplex 1 (D1, 5’-
CCACTGTGTTTGACCACTA-3’), RhoJ siRNA duplex 2 (D2, 5’-
AGAAACCTCTCACTTACGA-3’) and a negative control duplex (siControl) with no homology 
to any known human sequence (all synthesized by Eurogentec).  Transfections of siRNA 
duplexes were performed using either RNAiMAX lipofectamine (Invitrogen) at a final 
concentration of 0.3% (v/v) or GeneFECTOR™ (Venn Nova, Inc.) at a final concentration of 
0.5% (v/v), with duplexes at 10-25 nM.  The RNAiMAX was used for all experiments except for 
the organotypic tube forming assays and the phospho/total MLC blotting.  For transfecting 
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HUVEC in 10 cm culture dishes, 106 HUVEC were seeded on to gelatin-coated dishes one day 
before transfection. For one 10 cm dish the transfection mix was prepared by firstly mixing the 
appropriate amount of duplex in a final volume of 680 μl of optiMEM (Invitrogen). In a separate 
tube, 12 μl of RNAiMAX lipofectamine was diluted in 108 μl of optiMEM. After mixing gently, 
both mixtures were incubated at room temperature for 10 minutes. Then the two mixtures were 
combined, gently flicked and incubated for a further 10 minutes at room temperature. 
Meanwhile, the cells were washed twice with phosphate-buffered saline (PBS) before adding 3.2 
ml OptiMEM to the 10 cm plates. The final transfection mix was then added to the plate and 
tilted to ensure even distribution. Mock cells were transfected using the method above but with 
no siRNA included. After 4 hours of incubation at 5% CO2 at 37 °C, the transfection mix was 
replaced with normal HUVEC media containing no antibiotics. To transfect cells in 6 cm dishes 
or 6 well plates, the transfection mixes were scaled down according to their surface area. 
 
5 Lentiviral transduction of HUVEC 
Production of lentivirus 
HEK293T cells were used for lentiviral production.  2.5x106 cells were plated in sterile culture 
dishes (10 cm diameter) and the next day calcium-phosphate transfections were performed as 
follows. 20 µg transfer vector (pWPXL-GFP-daRhoJ or pWPI (GFP)), 15 µg packaging vector 
(psPAX2) and 6 µg envelope vector (pMD2G) were mixed with 450 µl distilled water and 63 µl 
2 M calcium chloride (CaCl2 6H2O) in a 5 ml tube. Then 500 µl of 2x HBS (1.6% (w/v) NaCl, 
0.074% (w/v) KCl, 0.027% (w/v) Na2HPO4 2H2O, 0.2% (w/v) dextrose, 1.0 % (w/v)HEPES; 
pH 7.05) was added dropwise with shaking and the mixture was incubated for 15 min at room 
temperature to allow precipitation to occur.  Prior to addition of this transfection mixture, the 
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media of the plated HEK293T cells was replaced with 10 ml fresh media.  The cells were then 
incubated in a humidified atmosphere with 5% CO2 at 37°C for 8 hours, the transfection mixture 
was then removed and replaced with 5 ml of fresh medium. After 48 hrs supernatant with virus 
was collected, centrifuged for 5 min at 1100 rpm, cleared through 0.45 µm-pore syringe filters 
and stored at -80°C until use. 
 
Infection of HUVEC 
106 HUVEC were seeded on gelatin-coated culture 10 cm dishes (0.1% (w/v) gelatin in PBS). 
The next day the medium was replaced with 7.5 ml of lentivirus supernatant supplemented with 
8 µg/ml polybrene (Sigma), bovine brain extract and 90µg/ml heparin.  Cells were then 
incubated for 24 hr, after which time the lentivirus supernatant was replaced with fresh medium 
and cells were left to grow for 2 days. This procedure typically resulted in infection of 90% for 
the GFP control cells and 40-60% for those infected with the GFP-daRhoJ virus.  GFP positive 
cells were then purified by flow cytometric sorting (MoFlo Cytomation fluorescence activated 
cell sorter).  
 
6 Expression of RhoGTPases in HEK293T cells 
In order to express various epitope tagged RhoGTPases HEK293T cells were transfected with 5 
µg of plasmid using the calcium phosphate transfection as described above in the section on 
lentiviral production. 
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7 Inhibition of ROCK and non-muscle myosin II 
The ROCK inhibitor Y27632 was used at a concentration of 10 μM and the non-muscle myosin 
II inhibitor was used at 5 μM.  These inhibitors were added to the media, where indicated, in the 
matrigel tube forming assay and Boyden chamber chemotaxis assay, it was added in the scratch 
wound assay at the time the scratch was made. 
 
8 Matrigel tube formation  
Natural matrigel (VWR) was thawed overnight on ice at 4 °C. The wells of a 12 well plate were 
wetted with PBS prior to adding 70 μl of matrigel. The basement membrane extract was allowed 
to solidify at 37°C for 30 minutes. Cells were harvested and seeded at a density of 1.4 x 105/well 
in HUVEC media. Cells were then incubated at 37°C with 5% CO2 for a further 24 hours. Tube 
formation was observed by taking pictures using Leica DM IL microscope and USB 2.0 2M Xli 
camera (Leica Microsystems, Houston).   The matrigel assays were quantified by counting the 
number of nodes with 1, 2, 3 or 4 branch-points from five fields of view from each condition at 
10 and 24 hour time points.   
 
9 Scratch wound assay 
In a 6 well plate coated with 0.1% (w/v) gelatin in PBS, HUVEC were seeded at cell density of 
1.75 x 105 and left overnight. Cells were then transfected with siRNA duplexes and two days 
after, pen marks were made along the bottom of the wells, then with 200 μl sterile pipette tips 
scratches perpendicular to the pen marks were made. Cells were washed and fresh HUVEC 
media containing 25 μg/ml of mitomycin C (Sigma) was added. Cells were incubated at 37°C 
with 5% CO2 for a further 24 hours. Cell migration was observed by taking pictures at 0, 4, 12 
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and 24 hours using using Leica DM IL microscope and USB 2.0 2M Xli camera.  To quantify 
wound closure, the areas of wounds were measured using ImageJ software.  For each condition 
the wounds at 0 hours were considered to be 100% open, the areas at subsequent time points 
were divided by the area measured at the 0 hour time point and the percentage of the wound still 
open calculated. 
 
10 Cell proliferation 
Four hours after siRNA transfection, cell were harvested and 1.5 x 104 cells were seeded in 1 ml 
of HUVEC media per well of a 24 well plates coated in 0.1% (w/v) gelatin in PBS. Four plates 
were prepared to count the cells 1-4 days after seeding. For each plate, cells from each condition 
were plated in triplicate. Cells were counted using a haemocytometer and DM IL microscope 
(Leica).  
 
11 Apoptosis 
Three days after siRNA transfection, apoptosis was assessed using the Annexin V-FITC staining 
kit (BD Pharmingen) according to the manufacturer’s instructions. Cells were stained in a 
volume of 100 μl 1 x binding buffer [10 x binding buffer: 0.1 M Hepes pH 7.4, 1.4 M NaCl, 25 
mM CaCl2] which contained 5 μl Annexin V-FITC and propidium iodide (Sigma) at 50 ng/ml. 
Cells were stained in the dark for 15 minutes before being analysed by FACS-Becton Dickson 
FACSCalibur (Becton and Dickson, USA) to detect apoptosis. 10,000 cells were analysed per 
condition. Green fluorescence was detected using FL1 channel and red fluorescence was 
detected using FL3 channel. Cell Quest Software (version 3.1f) displayed the results as a 
bivariate dot plot of Annexin V (FL1) and PI (FL3) fluorescence intensity. 
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12 Organotypic tube forming assay 
In the organotypic assay, HUVEC were co-cultured with confluent human dermal fibroblasts 
(HDF) in an assay as previously described 3, 4 using the Angiokit (TCS cell works).  In the case 
of siRNA knockdown, HUVEC were transfected with siRNA duplexes using GeneFECTOR™ 
(Venn Nova, Inc.) a day before seeding on to HDF which had been grown to confluence for 
seven days.  For HUVEC expressing either GFP or GFP-daRhoJ, lentivirally tranduced and GFP 
positive sorted HUVEC were seeded directly on to confluent HDF.  The co-cultures were 
incubated for 5 days and the HUVEC were visualized by staining wells using a mouse anti-
human CD31 Tubule Staining Kit (TCS CellWorks) according to the manufacturer’s protocol.   
Automated analysis was performed using the AngioSys software.  The number of tubules, total 
tubule length and number of branch points were measured in at least 9 microscopic fields. 
 
13 Cell contraction assay 
To measure physical contractility, contraction of cell-populated type I collagen gels was 
assessed, such an assay has been used to measure contractility of human fibroblasts 5 and 
endothelial cells 6. The cell contraction assay (Cell Biolabs, Inc., UK) was set up according to the 
manufacturer’s instructions. 24 hours after siRNA transfection, cells were harvested and 
resuspended in complete HUVEC medium at 3 x 106 cells/ml. The collagen gel lattice was 
prepared by mixing 1 part of cell suspension with 4 parts of ice-cold 3 mg/ml collagen gel 
solution. A volume of 0.5 ml of the cell-collagen mixture was added to each well of a 24 well 
plate and incubated for 1 hr at 37°C in 5% CO2. After collagen polymerization, 1 ml of HUVEC 
medium was added drop wise to each collagen gel lattice. After two days, stress had developed 
in the collagen matrix. Therefore at this point, to initiate cell contraction, the attached collagen 
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gels were gently released from the sides of the culture dishes with a sterile pipette tip. The degree 
of cell contraction was evaluated by measuring the diameter of the free-floating collagen gels 
after 5 days. 
 
14 Immunofluorescence  
F-actin and vinculin 
For staining subconfluent HUVEC, two days after siRNA transfection, cells were harvested and 
seeded at 20,000 cells/coverslip on coverslips coated in gelatin (0.1% (w/v) in PBS) and 
incubated for 4 hours at 37°C with 5% CO2 in complete medium before washing and fixing.   In 
order to fluorescently stain proteins during wound healing, two days after siRNA transfection, 5 
x 104 cells were seeded onto 13 mm gelatin-coated glass coverslips (VWR, Canada) in 24-well 
plates. The following day, the cells were wounded by scraping across the surface with 2 μL 
sterile pipette tips and washed once with PBS. Fresh media was added and the wounds were 
allowed to heal for 6 hours in 5% CO2 at 37°C before fixing. 
 
Prior to fixing, cells were gently washed with PBS.  They were then fixed with 4% (w/v) 
paraformaldehye (PFA) in PBS for 15 minutes. The cells were washed again before 
permeabilizing with 0.1% (v/v) triton-X-100 in PBS for 4 minutes. The cells were blocked in IF 
blocking buffer (3% (w/v) BSA, 10% (v/v) FCS, 0.1% (v/v) tween-20, 0.01 % (w/v) sodium 
azide in PBS) for one hour at room temperature. The cells were then incubated for one hour at 
room temperature in 20 μg/ml anti-vinculin antibody (mouse monoclonal, Sigma) diluted in IF 
blocking buffer. Cells were washed with PBS then incubated with phalloidin-TRITC (50 μg/ml, 
Invitrogen) and 4 µg/mL anti-mouse immunoglobulin Alexa-fluor 488 (Invitrogen) for 30 
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minutes at room temperature in IF blocking buffer. Coverslips were mounted using ProLong 
Gold Antifade reagent with DAPI (Invitrogen).    
 
For visualization of f-actin and focal adhesions in GFP and GFP-daRhoJ lentivirally transduced 
cells were performed as described above, except that the secondary antibody used to stain 
vinculin was 4 µg/mL anti-mouse immunoglobulin conjugated to Alexa-fluor 546 (Invitrogen).  
For these cells separate slides were used for vinculin and f-actin staining. 
 
Immunofluorescence of endogenous RhoJ 
For staining endogenous RhoJ, HUVECs were cultured on glass coverslips coated with 0.1 % 
(w/v) gelatin/PBS for 16 hrs (o/n). Cells were fixed and permeabilized with ice cold methanol for 
5 min and blocked in 4 % (w/v) BSA/PBS for 1 hr at room temperature.  Coverslips were 
incubated with primary antibodies diluted in 4 % (w/v) BSA/PBS for two hours at room 
temperature: anti-RhoJ (rabbit polyclonal antibody, generated as described below) in 
combination with anti-vinculin (mouse monoclonal, Sigma) or anti-pFAK Y397 (mouse 
monoclonal, BD Transduction Laboratories).  Coverslips were washed 2 x 5 min in PBST and 
was then incubated with secondary antibody [anti-mouse Alexa-fluor 546 and anti-rabbit Alexa-
fluor 488 (Invitrogen)] diluted in 4 % (w/v) BSA/PBS for 45 min. Cells were washed 3 x 5 min 
in PBST and finally in water.  Cells were mounted in ProLong Gold antifade reagent - mounting 
medium with DAPI (Invitrogen).  
 
All immunofluorescence was analysed using the Axiovert 100M confocal microscope and LSM 
510 software (Zeiss). LSM 510 software was used to calculate mean fluorescent instensity of a 
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particular channel using the following equation: mean intensity = sum of (number of positive 
pixels x intensity levels)/number of positive pixels.  Focal adhesions were manually counted 
using the cell-counter plugin tool of ImageJ to count the areas of vinculin staining in each cell. 
 
15 Riboprobe synthesis for in situ hybridization 
Riboprobes were synthesized from plasmids pGEM3Z-mRhoJ (mouse RhoJ 1-645 of coding 
region), pGEM3Z-mVWF (7838-8387 of coding region) and pGEM3Z-hRhoJ (human RhoJ 1-
645 of coding region).  Plasmid DNA was linearized to generate templates for sense and 
antisense probe generation. The linearized DNA was then purified from the enzymatic reaction 
with QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions. 1 μg 
of linearized DNA was transcribed and labelled with the DIG labelling kit (Roche Applied 
Science), then the probe was purified using mini quick spin columns (Roche Applied Science). 
 
16 Mouse embryo whole-mount in situ hybridization 
Mouse embryos were collected from matings of C57BL/6 mice at embryonic day (E) E9.5. 
Embryos were staged by assigning noon of the day that a vaginal plug is found as E0.5. The 
matings were set up and mice were culled at E9.5 by the Biomedical Services Unit at the 
University of Birmingham. The embryos were dissected out by removing the uterus from the 
mother, trimming the mesometrium. The decidual swelling was then removed from the uterus 
and placed in ice cold PBS. The embryos were carefully removed from the deciduas before 
removing the thin Deichert’s membrane from the embryos. The embryos were immediately 
transferred to freshly prepared 4% (w/v) PFA in DEPC-treated PBS at 4°C overnight whilst 
gently rocking. The embryos were then washed with DEPC-treated PBS before being dehydrated 
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through sequential 5 minute incubations at room temperature in 1 ml 25% (v/v), 50% (v/v), 75% 
(v/v) and then 100% methanol in 0.1% (v/v) tween-20 DEPC-treated PBS (PBST) and stored at -
20 °C. 
 
Whole mount in situ hybridization protocol was adapted from the protocol described by Piette et 
al 7. Mouse embryos were rehydrated back through sequential 5 minute incubations at room 
temperature in 1 ml 75% (v/v), 50% (v/v) and then 25% (v/v) methanol in 0.1% (v/v) tween-20 
DEPC-treated PBST and then 5 minutes in PBST with gentle rocking for all incubations.  
 
The embryos were then digested with 10 μg/ml of proteinase K (Sigma) in PBST for 15 minutes 
at room temperature and washed once with 2 mg/ml glycine (Sigma) in PBST. Embryos were 
rinsed once with PBST and washed a further 2 x 5 minutes with PBST before being re-fixed in 
4% (w/v) PFA / 0.2% (v/v) glutaldehyde in PBS for 20 minutes. The embryos were washed 2 x 5 
minutes with PBST and washed once with 50% hybridization buffer [50% (v/v) deionized 
formamide, 1% (w/v) blocking reagent, 5xSSC, 0.1 mg/ml heparin, 1 mg/ml torula RNA, 0.1% 
(w/v) CHAPS, adjusted to pH 5.5 with 1 M citric acid] / 50% PBST for 3 minutes. The embryos 
were then washed once in 100% hybridization buffer for 3 minutes and this was replaced with 
400 μl hybridization buffer and the embryos were prehybridized at 65°C for 3 hours. 500 ng of 
riboprobe was added to 100 μl of hybridization buffer and denatured at 95°C for 5 minutes and 
then added to the embryos and incubated over night at 65°C. The following day, the riboprobe 
mix was removed and the embryos were washed in 800 μl of hybridization buffer for 5 minutes 
at 70°C. Added to this solution was 400 μl of 2 x SSC (Sigma) pH 4.5 which was incubated for 5 
minutes at 70°C (this step was repeated 3 times leading to a total volume of 2 ml). The mix was 
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removed and the embryos were incubated in 2 x SSC pH 7 / 0.1% (w/v) CHAPS (Sigma) for 30 
minutes at 70°C. The embryos were then washed with Maleic Acid Buffer – Tween 20 (MABT) 
[0.1 M Maleic acid, 0.15 M NaCl, pH 7.5 using NaOH] in the following order: 2 x 10 minutes 
with MABT at room temperature,  2 x 30 minutes MABT at 70 °C, 2 x 10 minutes PBS at room 
temperature and finally for 5 minutes in PBST. 
 
Embryos were incubated in 1 ml of antibody buffer [10% (v/v) heat inactivated serum, 1% (w/v) 
blocking reagent (Roche applied science), 1 x PBST] for at least 2 hours whilst rocking gently at 
4°C.  This was removed and replaced with antibody buffer containing preblocked 1:500 anti-
digoxigenin conjugated to alkaline phosphatase antibody (Roche Applied Science) and incubated 
overnight at 4 °C whilst rocking gently. Embryos were rinsed and then washed 4 x 45 minutes 
with 4 ml of PBST/0.1% (w/v) BSA (Sigma) at room temperature. Embryos were then washed 2 
x 30 minutes in PBST and then 2 x 10 minutes in AP1 buffer [0.1 M NaCl, 0.1 M Tris pH 9.5, 50 
mM MgCl2] at room temperature. The AP1 buffer was replaced with 1 ml of BM purple (Roche 
applied science) and incubated in the dark until a purple signal has developed. The reaction was 
stopped by washing the embryos 2 x 15 minutes in stop solution [100 mM Tris Ph 7.4, 1 mM 
EDTA] at room temperature and dehydrated through a methanol series to 100% methanol as 
detailed above. Embryos were viewed and imaged using Leica MZ16 stereomicroscope and USB 
2.0 2M Xli camera (Leica) and stored at 4 °C indefinitely.  
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17 Fluorescent in situ hybridization on human tissue sections 
Paraffin embedded tissue sections were obtained from either Cancer Research UK (CRUK) 
histology service or SuperBiochips Inc. All solutions were DEPC treated. All reagents are from 
Sigma unless otherwise stated. 
 
Following removal of paraffin with Histoclear (National Diagnostics, UK) for 3 x 5 minutes, the 
tissues were rehydrated back through sequential 5-minute incubations at room temperature in 
100%, 75% (v/v), and then 25% (v/v) ethanol in H2O. Tissues were then washed for 1 minute in 
H2O and 10 minutes in PBS at room temperature. Tissues were re-fixed in 4% (w/v) 
Paraformaldehyde in PBS for 10 minutes at room temperature. Sections were then washed for 30 
minutes with PBS at 37 °C to ensure the right temperature for digestion. The tissue sections were 
then digested with 0.2% (w/v) Trypsin in PBS for 10 minutes at 37 °C. Following digestion, 
sections were rinsed once with PBS and then dehydrated through sequential 5 minute incubations 
at room temperature in 25% (v/v), 75% (v/v) and then 100% ethanol in H2O. Slides were allowed 
to air dry for 3 minutes before adding 50 μl of hybridization buffer [50% (v/v) deionized 
formamide, 2 x SSC, 0.005 M sodium phosphate, 10% (w/v) dextran sulphate, 500 ng 
digoxigenin labeled riboprobe in nuclease-free H2O] per slide. Sections were completely covered 
with RNase-free hybriwells (Invitrogen). The probe was then denatured by heating to 80 °C for 
75 seconds using PCR Express Thermal Cycler (Thermo Hybaid) before being incubated 
overnight at 37 °C. The following day, hyrbiwells were removed and sections were gently rinsed 
in 2 x SSC with 0.1% (v/v) tween-20. Tissues were then washed in 0.1 x SSC for 30 minutes at 
68 °C. Tissues were treated with 0.1 mg/ml RNase A in PBST for 15 minutes at room 
temperature then rinsed three times with PBST. Sections were blocked in blocking buffer [1/20 
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FCS in PBST] for 1 hour at room temperature. Tissue sections were then probed with 20 µg/ml 
of Ulex europeaus agglutinin I (UEAI) conjugated to fluorescein (Vector Labs) and 1 μg/ml anti-
digoxigenin conjugated to rhodamine (Roche) in blocking buffer for 1 hour. Sections were rinsed 
three times with PBST and then once with H2O. Slides were permanently mounted with Anti-
Fade Prolong Gold with DAPI (Invitrogen) and sections were analysed using Axiovert 100M 
laser scanning confocal microscope (Zeiss). 
 
18 RNA extraction, cDNA production and qPCR 
RNA from HUVEC, HASMC and hPC-PL was extracted using TRI reagent (Sigma) according 
to the manufacturer’s instructions.  cDNA prepared from 2 µg RNA in a volume of 40 µl High-
Capacity cDNA Archive kit (Applied Biosystems, UK) using the random primers according to 
the manufacturer’s instructions.  qPCR for human RhoJ and beta-actin was performed using the 
Exiqon probe based system (Roche) as using a Rotor-Gene (Corbett) as previously described 8. 
 
19 Preparing cell lysates 
For protein expression analysis from siRNA knockdown experiments and for analysing RhoJ 
expression in different cell types, cells were lysed in NP40 lysis buffer as described below.  48 - 
72 hours after siRNA transfection approximately 2 x 105 cells were harvested, washed with PBS 
and lysed in 30 μl of NP40 lysis buffer [1 % (v/v) NP40, 10 mM Tris pH 7.5, 150 mM NaCl, 1 
mM EDTA pH 8, 0.01% (w/v) sodium azide and 1 x protease inhibitor cocktail (Sigma)]. Tubes 
were vortexed for 10 seconds and incubated on ice for 30 minutes followed by centrifugation at 
20,000 g for 10 minutes at 4°C. Protein concentrations of the lysates were measured by DC 
BioRad protein assay kit (BioRad Laboratories). The supernatant was then transferred to a new 
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tube containing an equal volume of 2x SDS-PAGE sample buffer [100 mM Tris pH 6.8, 10% 
(w/v) SDS, 20% (v/v) glycerol, 0.2% (w/v) bromophenol blue, 20% (v/v) β-mercaptoethanol] 
and stored at -20°C.  In order to perform western blotting from lentivirally transduced HUVEC 
or transfected HEK293T cells, cells were lysed in Rho-assay buffer (1 % (v/v) NP40, 1 % (w/v) 
N-octyl-β-D-glucopyranoside, 25 mM HEPES pH 7.5, 30 mM MgCl2, 150 mM NaCl, protease 
inhibitors cocktail (Sigma), 10mM NaF, 2mM NaVO3) and processed as described in section 20 
below. 
 
20 RhoJ and Cdc42 activation assays 
Preparation of GST-PBD beads: GST-PBD was expressed in E. coli strain BL21 (DE3) and 
purified according to standard methods.  pGEX KG-PBD was used to produce glutathione S-
Transferase – Pak1 p21-binding domain (GST-PBD, the PBD encoded amino acids 1-254 of 
Rattus norvegicus PAK1 which encompasses the CRIB domain).  Briefly, liquid cultures of E. 
coli were incubated with shaking at 30ºC until they reached the mid-log phase growth, when they 
were induced with 0.3 mM IPTG for 2.5 hrs.  Bacteria were harvested, washed and frozen as a 
pellet at -80ºC. Subsequently, bacteria were thawed on ice, lysed with ice-cold E. coli lysis 
buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol (DTT) and 1 
mM phenylmethylsulfonyl fluoride (PMSF)) and ultra-sonicated for 3 min (Ultrasonicator Vibra 
CellTM, Sonics & Materials).  After sonication Triton X100 was added to final concentration of 
1% (v/v) and left on ice for 30 min before centrifugation.  Lysates were clarified by 
centrifugation at 21910 x g for 10 minutes at 4ºC. Then the supernatant was collected and mixed 
with glycerol to give a final concentration of glycerol 50% (v/v) and stored at -20ºC.  Prior to 
each experiment GST-PBD was bound in batch to glutathione-agarose (Sigma); for each 
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pulldown, 5 μg of GST-PBD was bound to glutathione-agarose by incubating sufficient bacterial 
lysate with 12.5 μl of packed beads in E. coli lysis buffer in a volume of 125 μl and rotated on 
wheel for 45 min at 4ºC.  They were then washed 3 times with Rho-assay buffer (1 % (v/v) 
NP40, 1 % (w/v) N-octyl-β-D-glucopyranoside, 25 mM HEPES pH 7.5, 30 mM MgCl2, 150 
mM NaCl, protease inhibitors cocktail (Sigma), 10mM NaF, 2mM NaVO3) and finally diluted 
with this buffer to give 25 % (v/v) slurry. The beads were then ready for the Rho GTPase pull-
down assay. 
 
VEGF-A stimulation assay: HUVEC were cultured on gelatin-coated 10 cm plates and starved in 
M199 medium (supplemented with 4 mM glutamine) for 1 hour. After starving the cells, M199 
medium containing 10 ng/ml VEGF-A (Peprotech) was added in a total volume of 5 ml per plate 
for the specified time period. After treatment medium was quickly removed, the plates placed on 
ice and 200 μl of Rho-assay lysis buffer was added. Cells were scraped in lysis buffer and 
incubated in 1.5 ml eppendorf on ice for 10 min. Then lysates were clarified by centrifugation at 
21910 g for 5 minutes at 4ºC.  20 μl of each sample lysate was mixed with equal amount of 2x 
SDS sample-loading buffer (100 mM Tris-Cl, pH 6.8, 20% (v/v) β-mercaptoethanol, 4% (w/v) 
SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol) and the remainder was mixed with 
GST-PBD glutathione agarose beads. Samples were placed on a rotating wheel and the pull-
down performed for 45 min at 4ºC. Then the beads were washed 3 times with 1 ml of Rho-assay 
lysis buffer and resuspended in 30 μl of 2x SDS sample-loading buffer.  Finally samples were 
subjected to the SDS-PAGE and western blotted with RhoJ or Cdc42 specific antibodies, as 
described below.  Densitometry was performed using ImageJ software.  For each band, mean 
grey values were determined, background values subtracted, and the resulting values used to 
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calculate the amount of activated Rho GTPase relative to total Rho GTPase for each time point.  
Time point 0 was normalised to 1, and the values for all other time points adjusted accordingly.  
 
21 SDS-polyacrylamide gel electrophoresis and western blotting 
Samples were subjected to SDS-PAGE and western blotting using standard techniques. Primary 
antibodies used were as indicated with horseradish peroxidase (HRP) conjugated secondary 
antibodies were polyclonal goat anti-mouse immunoglobulins as noted above.  The western blots 
were developed with ECL Western Blotting Detection Reagents (GE Healthcare) or Supersignal 
(Pierce) and exposed to Hyperfilm MP (Amersham Biosciences). 
 
22 Phospho-myosin light chain assays 
HUVEC were either mock transfected or transfected with siControl, RhoJ siRNA D1 or D2 in 6-
well plates at a density of 1.5x105 using GeneFECTOR™ (Venn Nova, Inc.) according to the 
manufacturer’s recommendations.  One day after transfection, 5x105 cells were plated on 6 cm 
plates coated with 600 μl growth factor reduced matrigel (VWR) diluted 1:1 with PBS and 
cultured in Optimized Medium (TCS CellWorks) for a further 24-48 hours.  To harvest cells, 
plates were placed on ice, the media was removed and 300 μl of 2x Laemmli lysis buffer [80 mM 
Tris-Cl, pH 7.5, 4% (v/v) β-mercaptoethanol, 2% (w/v) SDS, 10% (v/v) glycerol, 10mM sodium 
fluoride, 1mM sodium vanadate, 10mM sodium β-glycerophosphate, 0.5mM PMSF and 
Complete-EDTA free protease (Roche, Diagnostics GmbH)] was added.  After scraping, the 
lysate was transferred to a 1.5 ml tube and immediately snap frozen on dry ice.  Lysates were 
then boiled from frozen for 5 minutes, sonicated for 15s and then centrifuged for 30 minutes at 
4ºC.  The supernatant was transferred to a new tube, and 225 lysate was added to 75 μl NuPage 
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LDS load (Invitrogen).  This was then subjected to SDS-polyacrylamide gel electrophoresis and 
western blotting.  Membranes were blocked in 5% (w/v) BSA in TBST and then probed with 
either phospho-MLC2 (thr18/ser19 NEB signalling) or pan-MLC2 (Santa Cruz), followed by an 
HRP conjugated anti-rabbit immuboglobulin antisera and the ECL Plus detection System (GE 
Healthcare-Amersham).   
 
23 Development of RhoJ antiserum for immunofluorescence 
To make polyclonal anti-RhoJ antibodies, recombinant fusion protein maltose binding protein 
(MBP)-wtRhoJ was produced and used as the immunogen.  Wild type RhoJ without the region 
encoding the CAAX box (wtRhoJ-CAAX) was cloned into pMAL-2CE.  This plasmid was 
transformed into BL21 (DE3) pLys S E. coli, and bacterial extract containing MBP-wtRhoJ-
CAAX was prepared according to the protocol described above for GST-PBD.  MBP-wtRhoJ-
CAAX was purified using amylose beads using standard protocols, and used for immunisations 
performed by Harlan Sera Lab (Cancer Research UK Central Services, Clare Hall). Rabbits were 
given 6 injections according to the following schedule. The primary immunisation used 400 μg 
in complete Freund’s adjuvant, and the following 5 injections contained 100 μg of immunogen in 
incomplete Freund’s adjuvant and were given every two weeks thereafter. The rabbits were 
terminally bled after one week of the 6th injection.  The antiserum was purified by first removing 
the MBP specific antibodies and then purifying RhoJ specific antibodies by incubating with 
GST-wtRhoJ-CAAX bound to Polyvinylidene fluoride (PVDF) membrane.   
 
To purify a batch of antibody the following was performed in each of six 1.5 ml tubes.  Bacterial 
extract containing 15 μg of MBP protein was incubated with 25 µl packed amylose beads (NEB) 
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in a final volume of approximately 0.5 ml of E. coli washing buffer (50 mM Tris-HCl, pH 7.5, 
50 mM NaCl, 5 mM MgCl2) supplemented with 1mM PMSF (Sigma) and rotated on a wheel for 
1 hr at 4 °C.  The beads were washed 3 times with 1ml of E. coli washing buffer and then 
blocked in 3 % (w/v) bovine serum albumin (BSA)/ tris-buffered saline tween (TBST) for 1 hr at 
4 °C.  To remove MBP specific antibodies, 0.5 ml of the MBP-RhoJ specific antiserum was then 
incubated with these beads by rotation on a wheel for 1 hr at 4 °C. The pre-cleared antiserum 
was collected and the amylose beads washed 4 times with 1 ml of TBST, the pre-cleared 
antiserum was pooled with the washes and the total volume adjusted to 5 ml with TBST, to give 
a final total of 30 ml. 
 
10 µg of GST-wtRhoJ-CAAX was loaded in each well of 6 polyacrylamide gels (12%), proteins 
were transferred to PVDF membranes and stained with Ponceau S dye (Sigma) to identify GST-
wtRhoJ-CAAX. The strips of membrane containing GST-wtRhoJ-CAAX were cut out and 
blocked in 3 % (w/v) BSA/TBST for 1 hr at room temperature.  Then each of the 6 membrane 
strips was incubated separately with 5 ml pre-cleared antiserum over night in the presence of 3 
mM NaN3.  Membranes were washed 3 x 10 min with TBST, 1 x 10 min with high salt TBST 
(650 mM NaCl) and 3 x 10 min with TBS.  The strips were then combined and bound antibody 
was eluted in 3 ml of 100 mM glycine (pH 2.5) incubated with the membrane for 7 min on ice 
rotating. The solution was collected and neutralised with 1 M Tris-Cl (pH 9.5). Then the 
membrane was subjected to a second elution of the antibody with 3 ml of 100 mM glycine (pH 
2.5) and incubated for a further 5 min, collected and neutralised as above. Purified antibodies 
from each elution were stored separately, and supplemented with 3mM NaN3 and 4 % (w/v) 
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BSA at 4 °C. The quality of the purified antiserum was checked by western blotting and 
immunofluorescence using negative control duplex or RhoJ specific siRNA transfected HUVEC. 
 
24 Chemotaxis using the Boyden chamber 
Chemotaxis was assayed using a 48-well modified Boyden chamber (Neuro Probe, USA) with 8 
μm pore size polycarbonate nucleopore filters (Neuro Probe, USA). Filters were coated with 
gelatin (0.1% (w/v) in PBS) and placed over a lower chamber containing 30 μl per well of 
complete HUVEC media as the chemoattractant factor. Cells were incubated in serum-free 
media for 30 minutes before the assay. Cells were harvested and 2 x 104 cells were seeded per 
well of the upper chamber in 50 μl basal media of M199 and 4 mM glutamine containing 1% 
(v/v) fetal bovine serum. After 5 hours incubation at 37°C with 5% CO2, the filters were 
removed, fixed in 100% methanol and stained with 100 ng/ml DAPI (Sigma) in PBS for 1 
minute at room temperature. The filters were then washed with PBS and placed onto a glass slide 
and non-migrated cells were wiped away with a wet cotton swab. Cells that migrated through the 
pores towards the chemoattractant were viewed using Axiovert 100M confocal microscope and 
LSM 510 software (Zeiss). The sum of migrated cells in five random areas for each well was 
calculated for at least 5 replicate wells of each condition.  
 
25 Statistical analyses 
All experiments were performed at least 3 times with similar results.  Data is plotted with error 
bars representing standard error of the mean.  In order to test for statistical differences in the 
data, the Kruskal-Wallis test was used, in order to compare defined pairs of groups, the Mann-
Witney test was performed, except for the scratch wound and gel contraction assays where the 
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Student T test was used.  Statistical significance is denoted as follows: *** p<0.001, ** p= 0.001 
to 0.01 and * p=0.01 to 0.05. To analyse VEGF mediated activation of RhoJ and Cdc42 the 
Wilcoxon signed-rank test was used to compare data from each timepoint with time zero which 
was normalized to 1.   All calculations were performed using the Prism software (GraphPad). 
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